A Systems Pharmacology Model for Predicting Effects of Factor Xa Inhibitors in Healthy Subjects: Assessment of Pharmacokinetics and Binding Kinetics

Publisher： John Wiley & Sons Inc

E-ISSN： 2163-8306|4|11|650-659

ISSN： 2163-8306

Source： Cpt: Pharmacometrics & Systems Pharmacology, Vol.4, Iss.11, 2015-11, pp. : 650-659

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Bioavailability and Safety of the Factor Xa Inhibitor Edoxaban and the Effects of Quinidine in Healthy Subjects

By  

Clinical Pharmacology In Drug Development, Vol. 2, Iss. 4, 2013-10 ,pp. : 358-366

John Wiley & Sons Inc

Access to resources Recommend Favorite

Clinical Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Darexaban, an Oral Direct Factor Xa Inhibitor, in Healthy Elderly Japanese Subjects

By  

Clinical Pharmacology In Drug Development, Vol. 2, Iss. 4, 2013-10 ,pp. : 328-335

John Wiley & Sons Inc

Access to resources Recommend Favorite

Clinical Pharmacology of Direct and Indirect Factor Xa Inhibitors

By Rupprecht Hans-Juergen   Blank Ralf  

Drugs, Vol. 70, Iss. 16, 2010-11 ,pp. : 2153-2170

Adis International

Access to resources Recommend Favorite

Comparative Pharmacodynamics and Pharmacokinetics of Oral Direct Thrombin and Factor Xa Inhibitors in Development

By Eriksson Bengt I.  

Clinical Pharmacokinetics, Vol. 48, Iss. 1, 2009-01 ,pp. : 1-22

Adis International

Access to resources Recommend Favorite

Inhibitors of Factor Xa

By  

Expert Opinion on Therapeutic Patents, Vol. 11, Iss. 5, 2001-05 ,pp. : 891-895

Informa Healthcare

Access to resources Recommend Favorite